<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771637</url>
  </required_header>
  <id_info>
    <org_study_id>20210213</org_study_id>
    <nct_id>NCT04771637</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Perioperative Internal Environment and Rehabilitation of Patients Undergoing Gastrointestinal Malignant Tumor Resection</brief_title>
  <official_title>Effect of Dexmedetomidine on Perioperative Internal Environment and Rehabilitation of Patients Undergoing Gastrointestinal Malignant Tumor Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine is a highly selective alpha2-adrenergic receptor agonist with sedative,&#xD;
      analgesic, anti-anxiety, and inhibitory sympathetic nerve excitation properties. It is&#xD;
      commonly used in clinical anesthesia and intensive care.Radical gastrectomy for&#xD;
      gastrointestinal malignant tumors is a common major operation in clinical practice, with long&#xD;
      operation time, great trauma and strong stress response of patients. Dexmedetomidine is often&#xD;
      used in general anesthesia during such operations, but its long-term use or large dose may&#xD;
      produce certain side effects.Common side effects of dexmedetomidine include bradycardia and&#xD;
      hypotension, etc. Previous studies have reported that dexmedetomidine can prolong QT interval&#xD;
      and is at risk of causing tip torsion type ventricular tachycardia.Abnormal Potassium may&#xD;
      affect myocardial repolarization and increase the risk of tip torsion ventricular&#xD;
      tachycardia.The main purpose of this study was to observe the effects of long-term use of&#xD;
      dexmedetomidine on perioperative internal environment such as electrolyte and rehabilitation&#xD;
      indicators during radical general anesthesia for gastrointestinal malignancy, and the&#xD;
      secondary purpose was to explore the optimal dose of dexmedetomidine for general anesthesia&#xD;
      for patients undergoing radical general anesthesia for gastrointestinal malignancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>age</measure>
    <time_frame>perioperative</time_frame>
    <description>the age(years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight</measure>
    <time_frame>perioperative</time_frame>
    <description>weight(kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>perioperative</time_frame>
    <description>height(m)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sex</measure>
    <time_frame>perioperative</time_frame>
    <description>sex(male/female)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASA status</measure>
    <time_frame>perioperative</time_frame>
    <description>ASA status of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>internal environment</measure>
    <time_frame>Day 1</time_frame>
    <description>the concentrations of sodium(mmol/L), lactate(mmol/L), potassium(mmol/L), calcium(mmol/L), base excess(mmol/L), base excess in the extracellular fluid compartment(mmol/L) were measured before the dexmedetomidine infusion (t1), 1 h after the surgery began (t2), at the end of the surgery (t3), and 1 h after transfer to the PACU (t4), 24h after the surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>drugs</measure>
    <time_frame>1 day</time_frame>
    <description>the dosage of propofol, remifentanil and ephedrine</description>
  </other_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>into PACU 30 minutes</time_frame>
    <description>records the systolic blood pressure(mmHg), diastolic blood pressure(mmHg), and mean blood pressure(mmHg) of preoperative (T1), after infusion of loading dose of dexmedetomidine (T2), operation start (T3), operation start 5 min (T4), operation start 10 min (T5), operation start 1 h (T6), operation end(T7), immediately after extubation (T8), 5 min after extubation (T9) and into PACU 30 minutes (T10)</description>
  </other_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>into PACU 30 minutes</time_frame>
    <description>records the heart rate(beats/minute) of preoperative (T1), after infusion of loading dose of dexmedetomidine (T2), operation start (T3), operation start 5 min (T4), operation start 10 min (T5), operation start 1 h (T6), operation end(T7), immediately after extubation (T8), 5 min after extubation (T9) and into PACU 30 minutes (T10)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Perioperative</condition>
  <condition>Electrolyte</condition>
  <arm_group>
    <arm_group_label>control with normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients</description>
    <arm_group_label>dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient</description>
    <arm_group_label>dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients</description>
    <arm_group_label>dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients</description>
    <arm_group_label>control with normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. American Society of Anesthesiologists (ASA) physical status I or II;&#xD;
&#xD;
          2. age between 50-75 years, and a body mass index (BMI) between 18.5-28 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whoused hormones or drugs that have a hypoglycemic nature during the&#xD;
             preoperative state, or had bradycardia, arrhythmia, hypotension, abnormal liver or&#xD;
             kidney function, pancreatic disease, neuroendocrine malignancy, intraoperative blood&#xD;
             transfusion;&#xD;
&#xD;
          2. Patients who refused participation and those who needed intensive care after the&#xD;
             surgery were also excluded from the study;&#xD;
&#xD;
          3. Patients who had severe internal environmental disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Electrolyte</keyword>
  <keyword>Haemodynamics</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Internal environment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

